{
  "id": "5c6f15577c78d69471000053",
  "type": "yesno",
  "question": "Is galcanezumab effective for treatment of migraine?",
  "ideal_answer": "Yes. Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide that is used for migraine prevention.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29616494",
    "http://www.ncbi.nlm.nih.gov/pubmed/30341990",
    "http://www.ncbi.nlm.nih.gov/pubmed/29310444",
    "http://www.ncbi.nlm.nih.gov/pubmed/29432219",
    "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
    "http://www.ncbi.nlm.nih.gov/pubmed/30182284",
    "http://www.ncbi.nlm.nih.gov/pubmed/29089894",
    "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
    "http://www.ncbi.nlm.nih.gov/pubmed/30413151",
    "http://www.ncbi.nlm.nih.gov/pubmed/29697153",
    "http://www.ncbi.nlm.nih.gov/pubmed/29848108",
    "http://www.ncbi.nlm.nih.gov/pubmed/30446596",
    "http://www.ncbi.nlm.nih.gov/pubmed/30378008"
  ],
  "snippets": [
    {
      "text": "Importance: Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusions and Relevance: Monthly subcutaneous injections of galcanezumab, both 120 mg and 300 mg, demonstrated efficacy (repeated-measures analysis) for the preventive treatment of migraine and support further development in larger phase 3 studies. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE OF REVIEW: Monoclonal antibodies (mAbs) targeting the calcitonin-gene-related peptide (CGRP) pathway have been developed for episodic and chronic migraine prevention, either through binding the CGRP ligand (eptinezumab, fremanezumab, galcanezumab) or the CGRP receptor (erenumab).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29432219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background Safety findings from a Phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (NCT02163993) are reported here.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29310444",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29310444",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab). To date, these monoclonal antibodies have shown promising efficacy in clinical trials, with no major safety concerns. If ongoing long-term studies show that their efficacy can be maintained, this may herald a new era for effective antimigraine therapies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29697153",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29616494",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Introduction Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29848108",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29848108",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Galcanezumab induced a robust, dose-dependent, and durable inhibition of capsaicin-induced increase in DBF, supporting the continued clinical development of galcanezumab for prophylaxis in migraine patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29089894",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.Based on the results of this meta-analysis, CGRP monoclonal antibodies significantly reduced the monthly migraine days and acute migraine-specific medication. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30182284",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Importance\nGalcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab appears efficacious, safe, and well tolerated for the preventive treatment of chronic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nGalcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (CGRP) and has demonstrated efficacy in reducing migraine headache days (MHD) in patients with episodic and chronic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30341990",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nGalcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (\u22646-month of treatment) a reduction in the number of migraine headache days and improved patients' functioning.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30413151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION\nTwelve months of treatment with self-administered injections of galcanezumab was safe and associated with a reduction in the number of monthly migraine headache days.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30413151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusions and Relevance\nMonthly subcutaneous injections of galcanezumab, both 120 mg and 300 mg, demonstrated efficacy (repeated-measures analysis) for the preventive treatment of migraine and support further development in larger phase 3 studies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Importance Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (\u22646-month of treatment) a reduction in the number of migraine headache days and improved patients' functioning.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30413151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (CGRP) and has demonstrated efficacy in reducing migraine headache days (MHD) in patients with episodic and chronic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30341990",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Both galcanezumab dose groups demonstrated greater overall mean reduction in the number of monthly MHDs compared to placebo (placebo -2.7, galcanezumab 120 mg -4.8, galcanezumab 240 mg -4.6) (<br><b>CONCLUSIONS</b>: Both doses of galcanezumab were superior to placebo in reducing the number of monthly MHDs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab appears efficacious, safe, and well tolerated for the preventive treatment of chronic migraine.<br><b>CLINICALTRIALSGOV IDENTIFIER</b>: NCT02614261.<br><b>CLASSIFICATION OF EVIDENCE</b>: This interventional study provides Class I evidence that galcanezumab is superior to placebo in the reduction of the number of monthly MHDs.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In September 2018, the US FDA approved galcanezumab as a once-monthly subcutaneous injection for the preventive treatment of migraine in adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30378008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of galcanezumab leading to its first approval for the preventive treatment of migraine in adults.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30378008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Galcanezumab appears efficacious, safe, and well tolerated for the preventive treatment of chronic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446596",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of galcanezumab leading to its first approval for the preventive treatment of migraine in adults.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30378008",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Twelve months of treatment with self-administered injections of galcanezumab was safe and associated with a reduction in the number of monthly migraine headache days.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30413151",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}